Hepatic insulin resistance and nonalcoholic fatty liver disease

Insulin Resistance: Symptoms, Causes and Treatment

Volumn , Issue , 2010, Pages 1-44

  Aguila, Marcia Barbosa ^a   Fernandes Santos, Caroline ^a   Pinheiro Mulder, Alessandra Da Rocha ^a   Faria, Tatiane Da Silva ^a   Mandarim De Lacerda, Carlos Alberto ^a  

^a STATE UNIVERSITY OF RIO DE JANEIRO   (Brazil)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 84877885445     PISSN: None     EISSN: None     Source Type: Book    
DOI: None     Document Type: Chapter

References (237)

1. Charlton, M. Nonalcoholic fatty liver disease: a review of current understanding and future impact. Clin Gastroenterol Hepatol, 2004, 2, 1048-1058.
2. Cave, M; Deaciuc, I; Mendez, C; Song, Z; Joshi-Barve, S; Barve, S; McClain, C. Nonalcoholic fatty liver disease: predisposing factors and the role of nutrition. J Nutr Biochem, 2007, 18, 184-195.
3. Mayerson, AB; Hundal, RS; Dufour, S; Lebon, V; Befroy, D; Cline, GW; Enocksson, S; Inzucchi, SE; Shulman, GI; Petersen, KF. The effects of rosiglitazone on insulin sensitivity, lipolysis, and hepatic and skeletal muscle triglyceride content in patients with type 2 diabetes. Diabetes, 2002, 51, 797-802.
4. Varela-Rey, M; Embade, N; Ariz, U; Lu, SC; Mato, JM; Martinez-Chantar, ML. Non-alcoholic steatohepatitis and animal models: understanding the human disease. Int J Biochem Cell Biol, 2009, 41, 969-976.
5. Falck-Ytter, Y; Younossi, ZM; Marchesini, G; McCullough, AJ. Clinical features and natural history of nonalcoholic steatosis syndromes. Semin Liver Dis, 2001, 21, 17-26.
6. Bellentani, S; Saccoccio, G; Masutti, F; Croce, LS; Brandi, G; Sasso, F; Cristanini, G; Tiribelli, C. Prevalence of and risk factors for hepatic steatosis in Northern Italy. Ann Intern Med, 2000, 132, 112-117.
7. McCullough, AJ. The clinical features, diagnosis and natural history of nonalcoholic fatty liver disease. Clin Liver Dis, 2004, 8, 521-533.
8. Bedogni, G; Miglioli, L; Masutti, F; Tiribelli, C; Marchesini, G; Bellentani, S. Prevalence of and risk factors for nonalcoholic fatty liver disease: the Dionysos nutrition and liver study. Hepatology, 2005, 42, 44-52.
9. Farrell, GC; Larter, CZ. Nonalcoholic fatty liver disease: from steatosis to cirrhosis. Hepatology, 2006, 43, S99-S112.
10. Strauss, RS; Barlow, SE; Dietz, WH. Prevalence of abnormal serum aminotransferase values in overweight and obese adolescents. J Pediatr, 2000, 136, 727-733.
11. Brunt, EM. Nonalcoholic steatohepatitis: definition and pathology. Semin Liver Dis, 2001, 21, 3-16.
12. Musso, G; Gambino, R; Cassader, M. Recent insights into hepatic lipid metabolism in non-alcoholic fatty liver disease (NAFLD). Prog Lipid Res, 2009, 48, 1-26.
13. Hays, T; Rusyn, I; Burns, AM; Kennett, MJ; Ward, JM; Gonzalez, FJ; Peters, JM. Role of peroxisome proliferator-activated receptor-alpha (PPARalpha) in bezafibrate-induced hepatocarcinogenesis and cholestasis. Carcinogenesis, 2005, 26, 219-227.
14. Browning, JD; Horton, JD. Molecular mediators of hepatic steatosis and liver injury. J Clin Invest, 2004, 114, 147-152.
15. Araya, J; Rodrigo, R; Videla, LA; Thielemann, L; Orellana, M; Pettinelli, P; Poniachik, J. Increase in long-chain polyunsaturated fatty acid n - 6/n - 3 ratio in relation to hepatic steatosis in patients with non-alcoholic fatty liver disease. Clin Sci (Lond), 2004, 106, 635-643.
16. Shimomura, I; Shimano, H; Korn, BS; Bashmakov, Y; Horton, JD. Nuclear sterol regulatory element-binding proteins activate genes responsible for the entire program of unsaturated fatty acid biosynthesis in transgenic mouse liver. J Biol Chem, 1998, 273, 35299-35306.
17. Wood, JM; Maibaum, J; Rahuel, J; Grutter, MG; Cohen, NC; Rasetti, V; Ruger, H; Goschke, R; Stutz, S; Fuhrer, W; Schilling, W; Rigollier, P; Yamaguchi, Y; Cumin, F; Baum, HP; Schnell, CR; Herold, P; Mah, R; Jensen, C; O'Brien, E; Stanton, A; Bedigian, MP. Structure-based design of aliskiren, a novel orally effective renin inhibitor. Biochem Biophys Res Commun, 2003, 308, 698-705.
18. Cheung, O; Sanyal, AJ. Abnormalities of lipid metabolism in nonalcoholic Fatty liver disease. Semin Liver Dis, 2008, 28, 351-359.
19. Jou, J; Choi, SS; Diehl, AM. Mechanisms of disease progression in nonalcoholic Fatty liver disease. Semin Liver Dis, 2008, 28, 370-379.
20. Chien, D; Dean, D; Saha, AK; Flatt, JP; Ruderman, NB. Malonyl-CoA content and fatty acid oxidation in rat muscle and liver in vivo. Am J Physiol Endocrinol Metab, 2000, 279, E259-265.
21. Chen, G; Liang, G; Ou, J; Goldstein, JL; Brown, MS. Central role for liver X receptor in insulin-mediated activation of Srebp-1c transcription and stimulation of fatty acid synthesis in liver. Proc Natl Acad Sci, U S A, 2004, 101, 11245-11250.
22. Denechaud, PD; Dentin, R; Girard, J; Postic, C. Role of ChREBP in hepatic steatosis and insulin resistance. FEBS Lett, 2008, 582, 68-73.
23. Dentin, R; Girard, J; Postic, C. Carbohydrate responsive element binding protein (ChREBP) and sterol regulatory element binding protein-1c (SREBP-1c): two key regulators of glucose metabolism and lipid synthesis in liver. Biochimie, 2005, 87, 81-86.
24. Shimomura, I; Bashmakov, Y; Horton, JD. Increased levels of nuclear SREBP-1c associated with fatty livers in two mouse models of diabetes mellitus. J Biol Chem, 1999, 274, 30028-30032.
25. Iizuka, K; Bruick, RK; Liang, G; Horton, JD; Uyeda, K. Deficiency of carbohydrate response element-binding protein (ChREBP) reduces lipogenesis as well as glycolysis. Proc Natl Acad Sci, U S A, 2004, 101, 7281-7286.
26. Gavrilova, O; Haluzik, M; Matsusue, K; Cutson, JJ; Johnson, L; Dietz, KR; Nicol, CJ; Vinson, C; Gonzalez, FJ; Reitman, ML. Liver peroxisome proliferator-activated receptor gamma contributes to hepatic steatosis, triglyceride clearance, and regulation of body fat mass. J Biol Chem, 2003, 278, 34268-34276.
27. Reddy, JK; Hashimoto, T. Peroxisomal beta-oxidation and peroxisome proliferator-activated receptor alpha: an adaptive metabolic system. Ann Rev Nutr, 2001, 21, 193-230.
28. Macdonald, GA; Prins, JB. Peroxisomal fatty acid metabolism, peroxisomal proliferator-activated receptors and non-alcoholic fatty liver disease. J Gastroenterol Hepatol, 2004, 19, 1335-1337.
29. Chalasani, N; Gorski, JC; Asghar, MS; Asghar, A; Foresman, B; Hall, SD; Crabb, DW. Hepatic cytochrome P450 2E1 activity in nondiabetic patients with nonalcoholic steatohepatitis. Hepatology, 2003, 37, 544-550.
30. Leclercq, IA; Farrell, GC; Field, J; Bell, DR; Gonzalez, FJ; Robertson, GR. CYP2E1 and CYP4A as microsomal catalysts of lipid peroxides in murine nonalcoholic steatohepatitis. J Clin Invest, 2000, 105, 1067-1075.
31. Hermesh, O; Kalderon, B; Bar-Tana, J. Mitochondria uncoupling by a long chain fatty acyl analogue. J Biol Chem, 1998, 273, 3937-3942.
32. Garcia-Ruiz, I; Rodriguez-Juan, C; Diaz-Sanjuan, T; Martinez, MA; Munoz-Yague, T; Solis-Herruzo, JA. Effects of rosiglitazone on the liver histology and mitochondrial function in ob/ob mice. Hepatology, 2007, 46, 414-423.
33. Kallwitz, ER; McLachlan, A; Cotler, SJ. Role of peroxisome proliferators-activated receptors in the pathogenesis and treatment of nonalcoholic fatty liver disease. World J Gastroenterol, 2008, 14, 22-28.
34. Kerner, J; Hoppel, C. Fatty acid import into mitochondria. Biochim Biophys Acta, 2000, 1486, 1-17.
35. Rinella, ME; Green, RM. The methionine-choline deficient dietary model of steatohepatitis does not exhibit insulin resistance. J Hepatol, 2004, 40, 47-51.
36. Day, CP; James, OF. Steatohepatitis: a tale of two "hits"? Gastroenterology, 1998, 114, 842-845.
37. Zamara, E; Novo, E; Marra, F; Gentilini, A; Romanelli, RG; Caligiuri, A; Robino, G; Tamagno, E; Aragno, M; Danni, O; Autelli, R; Colombatto, S; Dianzani, MU; Pinzani, M; Parola, M. 4-Hydroxynonenal as a selective pro-fibrogenic stimulus for activated human hepatic stellate cells. J Hepatol, 2004, 40, 60-68.
38. Rashid, A; Wu, TC; Huang, CC; Chen, CH; Lin, HZ; Yang, SQ; Lee, FY; Diehl, AM. Mitochondrial proteins that regulate apoptosis and necrosis are induced in mouse fatty liver. Hepatology, 1999, 29, 1131-1138.
39. Moncion, A; Truong, NT; Garrone, A; Beaune, P; Barouki, R; De Waziers, I. Identification of a 16-nucleotide sequence that mediates post-transcriptional regulation of rat CYP2E1 by insulin. J Biol Chem, 2002, 277, 45904-45910.
40. Emery, MG; Fisher, JM; Chien, JY; Kharasch, ED; Dellinger, EP; Kowdley, KV; Thummel, KE. CYP2E1 activity before and after weight loss in morbidly obese subjects with nonalcoholic fatty liver disease. Hepatology, 2003, 38, 428-435.
41. Furukawa, S; Fujita, T; Shimabukuro, M; Iwaki, M; Yamada, Y; Nakajima, Y; Nakayama, O; Makishima, M; Matsuda, M; Shimomura, I. Increased oxidative stress in obesity and its impact on metabolic syndrome. J Clin Invest, 2004, 114, 1752-1761.
42. Sanyal, AJ; Campbell-Sargent, C; Mirshahi, F; Rizzo, WB; Contos, MJ; Sterling, RK; Luketic, VA; Shiffman, ML; Clore, JN. Nonalcoholic steatohepatitis: association of insulin resistance and mitochondrial abnormalities. Gastroenterology, 2001, 120, 1183-1192.
43. Sumida, Y; Nakashima, T; Yoh, T; Furutani, M; Hirohama, A; Kakisaka, Y; Nakajima, Y; Ishikawa, H; Mitsuyoshi, H; Okanoue, T; Kashima, K; Nakamura, H; Yodoi, J. Serum thioredoxin levels as a predictor of steatohepatitis in patients with nonalcoholic fatty liver disease. J Hepatol, 2003, 38, 32-38.
44. Pessayre, D. Role of mitochondria in non-alcoholic fatty liver disease. J Gastroenterol Hepatol, 2007, 22 SUPPL 1, S20-27.
45. Chen, L; Zeng, Y; Yang, H; Lee, TD; French, SW; Corrales, FJ; Garcia-Trevijano, ER; Avila, MA; Mato, JM; Lu, SC. Impaired liver regeneration in mice lacking methionine adenosyltransferase 1A. FASEB J, 2004, 18, 914-916.
46. Watanabe, S; Yaginuma, R; Ikejima, K; Miyazaki, A. Liver diseases and metabolic syndrome. J Gastroenterol, 2008, 43, 509-518.
47. Arkan, MC; Hevener, AL; Greten, FR; Maeda, S; Li, ZW; Long, JM; Wynshaw-Boris, A; Poli, G; Olefsky, J; Karin, M. IKK-beta links inflammation to obesity-induced insulin resistance. Nat Med, 2005, 11, 191-198.
48. Pessayre, D; Fromenty, B. NASH: a mitochondrial disease. J Hepatol, 2005, 42, 928-940.
49. Tafani, M; Schneider, TG; Pastorino, JG; Farber, JL. Cytochrome c-dependent activation of caspase-3 by tumor necrosis factor requires induction of the mitochondrial permeability transition. Am J Pathol, 2000, 156, 2111-2121.
50. Feldstein, AE; Canbay, A; Angulo, P; Taniai, M; Burgart, LJ; Lindor, KD; Gores, GJ. Hepatocyte apoptosis and fas expression are prominent features of human nonalcoholic steatohepatitis. Gastroenterology, 2003, 125, 437-443.
51. Burt, AD; Mutton, A; Day, CP. Diagnosis and interpretation of steatosis and steatohepatitis. Semin Diagn Pathol, 1998, 15, 246-258.
52. Zaitoun, AM; Al Mardini, H; Awad, S; Ukabam, S; Makadisi, S; Record, CO. Quantitative assessment of fibrosis and steatosis in liver biopsies from patients with chronic hepatitis C. J Clin Pathol, 2001, 54, 461-465.
53. Marsman, H; Matsushita, T; Dierkhising, R; Kremers, W; Rosen, C; Burgart, L; Nyberg, SL. Assessment of donor liver steatosis: pathologist or automated software? Hum Pathol, 2004, 35, 430-435.
54. Oleszczuk, A; Spannbauer, M; Tannapfel, A; Bluher, M; Hengstler, J; Pietsch, UC; Schuhmacher, A; Wittekind, C; Hauss, JP; Schon, MR. Regenerative capacity differs between micro- and macrovesicular hepatic steatosis. Exp Toxicol Pathol, 2007, 59, 205-213.
55. Gramlich, T; Kleiner, DE; McCullough, AJ; Matteoni, CA; Boparai, N; Younossi, ZM. Pathologic features associated with fibrosis in nonalcoholic fatty liver disease. Hum Pathol, 2004, 35, 196-199.
56. Sherlock, S. Acute fatty liver of pregnancy and the microvesicular fat diseases. Gut 1983;24, 265-269.
57. Rolfes, DB; Ishak, KG. Acute fatty liver of pregnancy: a clinicopathologic study of 35 cases. Hepatology, 1985, 5, 1149-1158.
58. Bellman, MH; Hall, SM. Aetiology of Reye's syndrome. Arch Dis Child, 1983, 58, 670-672.
59. Bove, KE; McAdams, AJ; Partin, JC; Partin, JS; Hug, G; Schubert, WK. The hepatic lesion in Reye's syndrome. Gastroenterology, 1975, 69, 685-697.
60. Heubi, JE; Partin, JC; Partin, JS; Schubert, WK. Reye's syndrome: current concepts. Hepatology, 1987, 7, 155-164.
61. Rao, MS; Reddy, JK. Peroxisomal beta-oxidation and steatohepatitis. Semin Liver Dis, 2001, 21, 43-55.
62. Hale, TM; Shoichet, MJ; Bushfield, TL; Adams, MA. Time course of vascular structural changes during and after short-term antihypertensive treatment. Hypertension, 2003, 42, 171-176.
63. Sherlock, S. Alcoholic liver disease. Lancet, 1995, 345, 227-229.
64. Sanyal, AJ; Mofrad, PS; Contos, MJ; Sargeant, C; Luketic, VA; Sterling, RK; Stravitz, RT; Shiffman, ML; Clore, J; Mills, AS. A pilot study of vitamin E versus vitamin E and pioglitazone for the treatment of nonalcoholic steatohepatitis. Clin Gastroenterol Hepatol, 2004, 2, 1107-1115.
65. Marceau, P; Biron, S; Hould, FS; Marceau, S; Simard, S; Thung, SN; Kral, JG. Liver pathology and the metabolic syndrome X in severe obesity. J Clin Endocrinol Metab, 1999, 84, 1513-1517.
66. Burt, AD; MacSween, RN. Hepatic vein lesions in alcoholic liver disease: retrospective biopsy and necropsy study. J Clin Pathol, 1986, 39, 63-67.
67. Van Steenbergen, W; Lanckmans, S. Liver disturbances in obesity and diabetes mellitus. Int J Obes Relat Metab Disord, 1995, 19 SUPPL 3, S27-36.
68. Faloon, WW. Hepatobiliary effects of obesity and weight-reducing surgery. Semin Liver Dis, 1988, 8, 229-236.
69. Quigley, EM; Zetterman, RK. Hepatobiliary complications of malabsorption and malnutrition. Semin Liver Dis, 1988, 8, 218-228.
70. Samuel, VT; Liu, ZX; Qu, X; Elder, BD; Bilz, S; Befroy, D; Romanelli, AJ; Shulman, GI. Mechanism of hepatic insulin resistance in non-alcoholic fatty liver disease. J Biol Chem, 2004, 279, 32345-32353.
71. Gavrilova, O; Marcus-Samuels, B; Graham, D; Kim, JK; Shulman, GI; Castle, AL; Vinson, C; Eckhaus, M; Reitman, ML. Surgical implantation of adipose tissue reverses diabetes in lipoatrophic mice. J Clin Invest, 2000, 105, 271-278.
72. Kim, JK; Fillmore, JJ; Chen, Y; Yu, C; Moore, IK; Pypaert, M; Lutz, EP; Kako, Y; Velez-Carrasco, W; Goldberg, IJ; Breslow, JL; Shulman, GI. Tissue-specific overexpression of lipoprotein lipase causes tissue-specific insulin resistance. Proc Natl Acad Sci, U S A, 2001;98, 7522-7527.
73. Shimomura, I; Hammer, RE; Ikemoto, S; Brown, MS; Goldstein, JL. Leptin reverses insulin resistance and diabetes mellitus in mice with congenital lipodystrophy. Nature, 1999, 401, 73-76.
74. Kim, JK; Gavrilova, O; Chen, Y; Reitman, ML; Shulman, GI. Mechanism of insulin resistance in A-ZIP/F-1 fatless mice. J Biol Chem, 2000, 275, 8456-8460.
75. Dixon, JB; Bhathal, PS; O'Brien, PE. Nonalcoholic fatty liver disease: predictors of nonalcoholic steatohepatitis and liver fibrosis in the severely obese. Gastroenterology, 2001, 121, 91-100.
76. Yin, M; Gabele, E; Wheeler, MD; Connor, H; Bradford, BU; Dikalova, A; Rusyn, I; Mason, R; Thurman, RG. Alcohol-induced free radicals in mice: direct toxicants or signaling molecules? Hepatology, 2001, 34, 935-942.
77. Tsochatzis, E; Papatheodoridis, GV; Archimandritis, AJ. The evolving role of leptin and adiponectin in chronic liver diseases. Am J Gastroenterol, 2006, 101, 2629-2640.
78. Feldstein, AE; Werneburg, NW; Canbay, A; Guicciardi, ME; Bronk, SF; Rydzewski, R; Burgart, LJ; Gores, GJ. Free fatty acids promote hepatic lipotoxicity by stimulating TNF-alpha expression via a lysosomal pathway. Hepatology, 2004, 40, 185-194.
79. Reddy, JK. Nonalcoholic steatosis and steatohepatitis. III. Peroxisomal beta-oxidation, PPAR alpha, and steatohepatitis. Am J Physiol Gastrointest Liver Physiol, 2001, 281, G1333-1339.
80. Choi, SS; Diehl, AM. Hepatic triglyceride synthesis and nonalcoholic fatty liver disease. Curr Opin Lipidol, 2008, 19, 295-300.
81. Ruan, H; Miles, PD; Ladd, CM; Ross, K; Golub, TR; Olefsky, JM; Lodish, HF. Profiling gene transcription in vivo reveals adipose tissue as an immediate target of tumor necrosis factor-alpha: implications for insulin resistance. Diabetes, 2002, 51, 3176-3188.
82. Hotamisligil, GS. Inflammation and metabolic disorders. Nature, 2006, 444, 860-867.
83. Ueki, K; Kondo, T; Tseng, YH; Kahn, CR. Central role of suppressors of cytokine signaling proteins in hepatic steatosis, insulin resistance, and the metabolic syndrome in the mouse. Proc Natl Acad Sci, U S A, 2004;101, 10422-10427.
84. Hassanein, T; Frederick, T. Mitochondrial dysfunction in liver disease and organ transplantation. Mitochondrion, 2004, 4, 609-620.
85. Nagakawa, Y; Williams, GM; Zheng, Q; Tsuchida, A; Aoki, T; Montgomery, RA; Klein, AS; Sun, Z. Oxidative mitochondrial DNA damage and deletion in hepatocytes of rejecting liver allografts in rats: role of TNF-alpha. Hepatology, 2005, 42, 208-215.
86. Corda, S; Laplace, C; Vicaut, E; Duranteau, J. Rapid reactive oxygen species production by mitochondria in endothelial cells exposed to tumor necrosis factor-alpha is mediated by ceramide. Am J Respir Cell Mol Biol, 2001, 24, 762-768.
87. Friedman, SL. Molecular regulation of hepatic fibrosis, an integrated cellular response to tissue injury. J Biol Chem, 2000, 275, 2247-2250.
88. Ribeiro, PS; Cortez-Pinto, H; Sola, S; Castro, RE; Ramalho, RM; Baptista, A; Moura, MC; Camilo, ME; Rodrigues, CM. Hepatocyte apoptosis, expression of death receptors, and activation of NF-kappaB in the liver of nonalcoholic and alcoholic steatohepatitis patients. Am J Gastroenterol, 2004, 99, 1708-1717.
89. Wieckowska, A; Zein, NN; Yerian, LM; Lopez, AR; McCullough, AJ; Feldstein, AE. In vivo assessment of liver cell apoptosis as a novel biomarker of disease severity in nonalcoholic fatty liver disease. Hepatology, 2006, 44, 27-33.
90. Duvnjak, M; Lerotic, I; Barsic, N; Tomasic, V; Virovic Jukic, L; Velagic, V. Pathogenesis and management issues for non-alcoholic fatty liver disease. World J Gastroenterol, 2007, 13, 4539-4550.
91. Neuschwander-Tetri, BA; Caldwell, SH. Nonalcoholic steatohepatitis: summary of an AASLD Single Topic Conference. Hepatology, 2003, 37, 1202-1219.
92. Kershaw, EE; Flier, JS. Adipose tissue as an endocrine organ. J Clin Endocrinol Metab, 2004, 89, 2548-2556.
93. Berg, AH; Combs, TP; Du, X; Brownlee, M; Scherer, PE. The adipocyte-secreted protein Acrp30 enhances hepatic insulin action. Nat Med, 2001, 7, 947-953.
94. Maeda, N; Takahashi, M; Funahashi, T; Kihara, S; Nishizawa, H; Kishida, K; Nagaretani, H; Matsuda, M; Komuro, R; Ouchi, N; Kuriyama, H; Hotta, K; Nakamura, T; Shimomura, I; Matsuzawa, Y. PPARgamma ligands increase expression and plasma concentrations of adiponectin, an adipose-derived protein. Diabetes, 2001, 50, 2094-2099.
95. Maeda, N; Shimomura, I; Kishida, K; Nishizawa, H; Matsuda, M; Nagaretani, H; Furuyama, N; Kondo, H; Takahashi, M; Arita, Y; Komuro, R; Ouchi, N; Kihara, S; Tochino, Y; Okutomi, K; Horie, M; Takeda, S; Aoyama, T; Funahashi, T; Matsuzawa, Y. Diet-induced insulin resistance in mice lacking adiponectin/ACRP30. Nat Med, 2002, 8, 731-737.
96. Kadowaki, T; Yamauchi, T; Kubota, N; Hara, K; Ueki, K; Tobe, K. Adiponectin and adiponectin receptors in insulin resistance, diabetes, and the metabolic syndrome. J Clin Invest, 2006, 116, 1784-1792.
97. Hui, JM; Hodge, A; Farrell, GC; Kench, JG; Kriketos, A; George, J. Beyond insulin resistance in NASH: TNF-alpha or adiponectin? Hepatology, 2004, 40, 46-54.
98. Xu, A; Wang, Y; Keshaw, H; Xu, LY; Lam, KS; Cooper, GJ. The fat-derived hormone adiponectin alleviates alcoholic and nonalcoholic fatty liver diseases in mice. J Clin Invest, 2003, 112, 91-100.
99. Mendez-Sanchez, N; Chavez-Tapia, NC; Villa, AR; Sanchez-Lara, K; Zamora-Valdes, D; Ramos, MH; Uribe, M. Adiponectin as a protective factor in hepatic steatosis. World J Gastroenterol, 2005, 11, 1737-1741.
100. Kaser, S; Moschen, A; Cayon, A; Kaser, A; Crespo, J; Pons-Romero, F; Ebenbichler, CF; Patsch, JR; Tilg, H. Adiponectin and its receptors in non-alcoholic steatohepatitis. Gut, 2005, 54, 117-121.
101. Musso, G; Gambino, R; Durazzo, M; Biroli, G; Carello, M; Faga, E; Pacini, G; De Michieli, F; Rabbione, L; Premoli, A; Cassader, M; Pagano, G. Adipokines in NASH: postprandial lipid metabolism as a link between adiponectin and liver disease. Hepatology, 2005, 42, 1175-1183.
102. Vuppalanchi, R; Marri, S; Kolwankar, D; Considine, RV; Chalasani, N. Is adiponectin involved in the pathogenesis of nonalcoholic steatohepatitis? A preliminary human study. J Clin Gastroenterol, 2005, 39, 237-242.
103. Yamagishi, SI; Edelstein, D; Du, XL; Kaneda, Y; Guzman, M; Brownlee, M. Leptin induces mitochondrial superoxide production and monocyte chemoattractant protein-1 expression in aortic endothelial cells by increasing fatty acid oxidation via protein kinase A. J Biol Chem, 2001, 276, 25096-25100.
104. Leclercq, IA; Farrell, GC; Schriemer, R; Robertson, GR. Leptin is essential for the hepatic fibrogenic response to chronic liver injury. J Hepatol, 2002, 37, 206-213.
105. Paschos, P; Paletas, K. Non alcoholic fatty liver disease and metabolic syndrome. Hippokratia, 2009, 13, 9-19.
106. Yoneda, M; Mawatari, H; Fujita, K; Endo, H; Iida, H; Nozaki, Y; Yonemitsu, K; Higurashi, T; Takahashi, H; Kobayashi, N; Kirikoshi, H; Abe, Y; Inamori, M; Kubota, K; Saito, S; Tamano, M; Hiraishi, H; Maeyama, S; Yamaguchi, N; Togo, S; Nakajima, A. Noninvasive assessment of liver fibrosis by measurement of stiffness in patients with nonalcoholic fatty liver disease (NAFLD). Dig Liver Dis, 2008, 40, 371-378.
107. Wieckowska, A; Papouchado, BG; Li, Z; Lopez, R; Zein, NN; Feldstein, AE. Increased hepatic and circulating interleukin-6 levels in human nonalcoholic steatohepatitis. Am J Gastroenterol, 2008, 103, 1372-1379.
108. Yilmaz, Y; Dolar, E; Ulukaya, E; Akgoz, S; Keskin, M; Kiyici, M; Aker, S; Yilmaztepe, A; Gurel, S; Gulten, M; Nak, SG. Soluble forms of extracellular cytokeratin 18 may differentiate simple steatosis from nonalcoholic steatohepatitis. World J Gastroenterol, 2007, 13, 837-844.
109. Henderson, NC; Iredale, JP. Liver fibrosis: cellular mechanisms of progression and resolution. Clin Sci (Lond), 2007, 112, 265-280.
110. Clark, JM. The epidemiology of nonalcoholic fatty liver disease in adults. J Clin Gastroenterol, 2006, 40 SUPPL 1, S5-10.
111. Gieling, RG; Burt, AD; Mann, DA. Fibrosis and cirrhosis reversibility - molecular mechanisms. Clin Liver Dis, 2008, 12, 915-937, xi.
112. Iredale, JP; Benyon, RC; Pickering, J; McCullen, M; Northrop, M; Pawley, S; Hovell, C; Arthur, MJ. Mechanisms of spontaneous resolution of rat liver fibrosis. Hepatic stellate cell apoptosis and reduced hepatic expression of metalloproteinase inhibitors. J Clin Invest, 1998, 102, 538-549.
113. Desmet, VJ; Roskams, T. Cirrhosis reversal: a duel between dogma and myth. J Hepatol, 2004, 40, 860-867.
114. Benyon, RC; Iredale, JP. Is liver fibrosis reversible? Gut, 2000, 46, 443-446.
115. Hui, AY; Friedman, SL. Molecular basis of hepatic fibrosis. Expert Rev Mol Med, 2003, 5, 1-23.
116. Parola, M; Robino, G. Oxidative stress-related molecules and liver fibrosis. J Hepatol, 2001, 35, 297-306.
117. Jaeschke, H. Mechanisms of Liver Injury. II. Mechanisms of neutrophil-induced liver cell injury during hepatic ischemia-reperfusion and other acute inflammatory conditions. Am J Physiol Gastrointest Liver Physiol, 2006, 290, G1083-1088.
118. Castillo, T; Koop, DR; Kamimura, S; Triadafilopoulos, G; Tsukamoto, H. Role of cytochrome P-450 2E1 in ethanol-, carbon tetrachloride- and iron-dependent microsomal lipid peroxidation. Hepatology, 1992, 16, 992-996.
119. Jaeschke, H. Inflammation in response to hepatocellular apoptosis. Hepatology, 2002, 35, 964-966.
120. Canbay, A; Friedman, S; Gores, GJ. Apoptosis: the nexus of liver injury and fibrosis. Hepatology, 2004, 39, 273-278.
121. Watanabe, A; Hashmi, A; Gomes, DA; Town, T; Badou, A; Flavell, RA; Mehal, WZ. Apoptotic hepatocyte DNA inhibits hepatic stellate cell chemotaxis via toll-like receptor 9. Hepatology, 2007, 46, 1509-1518.
122. Friedman, SL. Mechanisms of hepatic fibrogenesis. Gastroenterology, 2008, 134, 1655-1669.
123. Paik, YH; Schwabe, RF; Bataller, R; Russo, MP; Jobin, C; Brenner, DA. Toll-like receptor 4 mediates inflammatory signaling by bacterial lipopolysaccharide in human hepatic stellate cells. Hepatology, 2003, 37, 1043-1055.
124. Winau, F; Hegasy, G; Weiskirchen, R; Weber, S; Cassan, C; Sieling, PA; Modlin, RL; Liblau, RS; Gressner, AM; Kaufmann, SH. Ito cells are liver-resident antigen-presenting cells for activating T cell responses. Immunity, 2007, 26, 117-129.
125. Gressner, AM. Perisinusoidal lipocytes and fibrogenesis. Gut, 1994, 35, 1331-1333.
126. Friedman, SL. Seminars in medicine of the Beth Israel Hospital, Boston. The cellular basis of hepatic fibrosis. Mechanisms and treatment strategies. N Engl J Med, 1993, 328, 1828-1835.
127. Henderson, NC; Forbes, SJ. Hepatic fibrogenesis: from within and outwith. Toxicology, 2008, 254, 130-135.
128. Friedman, SL. Hepatic stellate cells: protean, multifunctional, and enigmatic cells of the liver. Physiol Rev, 2008, 88, 125-172.
129. Parola, M; Marra, F; Pinzani, M. Myofibroblast - like cells and liver fibrogenesis: Emerging concepts in a rapidly moving scenario. Mol Aspects Med, 2008, 29, 58-66.
130. Zeisberg, M; Yang, C; Martino, M; Duncan, MB; Rieder, F; Tanjore, H; Kalluri, R. Fibroblasts derive from hepatocytes in liver fibrosis via epithelial to mesenchymal transition. J Biol Chem, 2007, 282, 23337-23347.
131. Forbes, SJ; Russo, FP; Rey, V; Burra, P; Rugge, M; Wright, NA; Alison, MR. A significant proportion of myofibroblasts are of bone marrow origin in human liver fibrosis. Gastroenterology, 2004, 126, 955-963.
132. Guyot, C; Lepreux, S; Combe, C; Doudnikoff, E; Bioulac-Sage, P; Balabaud, C; Desmouliere, A. Hepatic fibrosis and cirrhosis: the (myo)fibroblastic cell subpopulations involved. Int J Biochem Cell Biol, 2006, 38, 135-151.
133. Geerts, A. History, heterogeneity, developmental biology, and functions of quiescent hepatic stellate cells. Semin Liver Dis, 2001, 21, 311-335.
134. Yang, C; Zeisberg, M; Mosterman, B; Sudhakar, A; Yerramalla, U; Holthaus, K; Xu, L; Eng, F; Afdhal, N; Kalluri, R. Liver fibrosis: insights into migration of hepatic stellate cells in response to extracellular matrix and growth factors. Gastroenterology, 2003, 124, 147-159.
135. Melton, AC; Soon, RK Jr.; Park, JG; Martinez, L; Dehart, GW; Yee, HF, Jr. Focal adhesion disassembly is an essential early event in hepatic stellate cell chemotaxis. Am J Physiol Gastrointest Liver Physiol, 2007, 293, G1272-1280.
136. Schuppan, D; Ruehl, M; Somasundaram, R; Hahn, EG. Matrix as a modulator of hepatic fibrogenesis. Semin Liver Dis, 2001, 21, 351-372.
137. Wells, RG. The role of matrix stiffness in regulating cell behavior. Hepatology, 2008, 47, 1394-1400.
138. Pinzani, M; Marra, F. Cytokine receptors and signaling in hepatic stellate cells. Semin Liver Dis, 2001, 21, 397-416.
139. Friedman, SL. Cytokines and fibrogenesis. Semin Liver Dis, 1999, 19, 129-140.
140. Paradis, V; Dargere, D; Vidaud, M; De Gouville, AC; Huet, S; Martinez, V; Gauthier, JM; Ba, N; Sobesky, R; Ratziu, V; Bedossa, P. Expression of connective tissue growth factor in experimental rat and human liver fibrosis. Hepatology, 1999, 30, 968-976.
141. Gentilini, A; Marra, F; Gentilini, P; Pinzani, M. Phosphatidylinositol-3 kinase and extracellular signal-regulated kinase mediate the chemotactic and mitogenic effects of insulin-like growth factor-I in human hepatic stellate cells. J Hepatol, 2000, 32, 227-234.
142. Mayer, DC; Leinwand, LA. Sarcomeric gene expression and contractility in myofibroblasts. J Cell Biol, 1997, 139, 1477-1484.
143. Rockey, DC; Fouassier, L; Chung, JJ; Carayon, A; Vallee, P; Rey, C; Housset, C. Cellular localization of endothelin-1 and increased production in liver injury in the rat: potential for autocrine and paracrine effects on stellate cells. Hepatology, 1998, 27, 472-480.
144. Han, YP; Yan, C; Zhou, L; Qin, L; Tsukamoto, H. A matrix metalloproteinase-9 activation cascade by hepatic stellate cells in trans-differentiation in the three-dimensional extracellular matrix. J Biol Chem, 2007, 282, 12928-12939.
145. Schaefer, B; Rivas-Estilla, AM; Meraz-Cruz, N; Reyes-Romero, MA; Hernandez-Nazara, ZH; Dominguez-Rosales, JA; Schuppan, D; Greenwel, P; Rojkind, M. Reciprocal modulation of matrix metalloproteinase-13 and type I collagen genes in rat hepatic stellate cells. Amer J Pathol, 2003, 162, 1771-1780.
146. Washington, K; Wright, K; Shyr, Y; Hunter, EB; Olson, S; Raiford, DS. Hepatic stellate cell activation in nonalcoholic steatohepatitis and fatty liver. Hum Pathol, 2000, 31, 822-828.
147. Ludwig, J; Viggiano, TR; McGill, DB; Oh, BJ. Nonalcoholic steatohepatitis: Mayo Clinic experiences with a hitherto unnamed disease. Mayo Clin Proc, 1980, 55, 434-438.
148. Larter, CZ; Yeh, MM. Animal models of NASH: getting both pathology and metabolic context right. J Gastroenterol Hepatol, 2008, 23, 1635-1648.
149. Das, K; Kar, P. Non-alcoholic steatohepatitis. J Assoc Physicians India, 2005, 53, 195-199.
150. Adams, LA; Angulo, P. Role of liver biopsy and serum markers of liver fibrosis in non-alcoholic fatty liver disease. Clin Liver Dis, 2007, 11, 25-35, viii.
151. Liquori, GE; Calamita, G; Cascella, D; Mastrodonato, M; Portincasa, P; Ferri, D. An innovative methodology for the automated morphometric and quantitative estimation of liver steatosis. Histol Histopathol, 2009, 24, 49-60.
152. Souza-Mello, V; Mandarim-de-Lacerda, CA; Aguila, MB. Hepatic structural alteration in adult programmed offspring (severe maternal protein restriction) is aggravated by post-weaning high-fat diet. Br J Nutr, 2007, 98, 1159-1169.
153. Turlin, B; Ramm, GA; Purdie, DM; Laine, F; Perrin, M; Deugnier, Y; Macdonald, GA. Assessment of hepatic steatosis: comparison of quantitative and semiquantitative methods in 108 liver biopsies. Liver Int, 2009, 29, 530-535.
154. Garcia Urena, MA; Colina Ruiz-Delgado, F; Moreno Gonzalez, E; Jimenez Romero, C; Garcia Garcia, I; Loinzaz Segurola, C; Gonzalez, P; Gomez Sanz, R. Hepatic steatosis in liver transplant donors: common feature of donor population? World J Surg, 1998, 22, 837-844.
155. Wigger, HJ. Frozen section of liver in the diagnosis of Reye syndrome. Am J Surg Pathol, 1977, 1, 271-274.
156. Aguila, MB; Pinheiro, AR; Parente, LB; Mandarim-de-Lacerda, CA. Dietary effect of different high-fat diet on rat liver stereology. Liver Int, 2003, 23, 363-370.
157. Franzen, LE; Ekstedt, M; Kechagias, S; Bodin, L. Semiquantitative evaluation overestimates the degree of steatosis in liver biopsies: a comparison to stereological point counting. Mod Pathol, 2005, 18, 912-916.
158. Mandarim-de-Lacerda, CA. Stereological tools in biomedical research. An Acad Bras Cienc, 2003, 75, 469-486.
159. Feldmann, G. Critical analysis of the methods used to morphologically quantify hepatic fibrosis. J Hepatol, 1995, 22, 49-54.
160. Brunt, EM; Janney, CG; Di Bisceglie, AM; Neuschwander-Tetri, BA; Bacon, BR. Nonalcoholic steatohepatitis: a proposal for grading and staging the histological lesions. Am J Gastroenterol, 1999, 94, 2467-2474.
161. Turlin, B; Mendler, MH; Moirand, R; Guyader, D; Guillygomarc'h, A; Deugnier, Y. Histologic features of the liver in insulin resistance-associated iron overload. A study of 139 patients. Am J Clin Pathol, 2001, 116, 263-270.
162. Sanyal, AJ. AGA technical review on nonalcoholic fatty liver disease. Gastroenterology, 2002, 123, 1705-1725.
163. Brunt, EM. Pathology of nonalcoholic steatohepatitis. Hepatol Res, 2005, 33, 68-71.
164. Brunt, EM. Pathology of fatty liver disease. Mod Pathol, 2007, 20 SUPPL 1, S40-48.
165. Kotronen, A; Yki-Jarvinen, H. Fatty liver: a novel component of the metabolic syndrome. Arterioscler Thromb Vasc Biol, 2008, 28, 27-38.
166. Adams, LA; Lymp, JF; St Sauver, J; Sanderson, SO; Lindor, KD; Feldstein, A; Angulo, P. The natural history of nonalcoholic fatty liver disease: a population-based cohort study. Gastroenterology, 2005, 129, 113-121.
167. Kleiner, DE; Brunt, EM; Van Natta, M; Behling, C; Contos, MJ; Cummings, OW; Ferrell, LD; Liu, YC; Torbenson, MS; Unalp-Arida, A; Yeh, M; McCullough, AJ; Sanyal, AJ. Design and validation of a histological scoring system for nonalcoholic fatty liver disease. Hepatology, 2005, 41, 1313-1321.
168. Wieckowska, A; Feldstein, AE. Diagnosis of nonalcoholic fatty liver disease: invasive versus noninvasive. Semin Liver Dis, 2008, 28, 386-395.
169. Nakano, S; Nagasawa, T; Ijiro, T; Inada, Y; Tamura, T; Maruyama, K; Kuroda, J; Yamazaki, Y; Kusama, H; Shibata, N. Bezafibrate prevents hepatic stellate cell activation and fibrogenesis in a murine steatohepatitis model, and suppresses fibrogenic response induced by transforming growth factor-beta1 in a cultured stellate cell line. Hepatol Res, 2008, 38, 1026-1039.
170. DeLeve, LD; Wang, X; Kanel, GC; Atkinson, RD; McCuskey, RS. Prevention of hepatic fibrosis in a murine model of metabolic syndrome with nonalcoholic steatohepatitis. Am J Pathol, 2008, 173, 993-1001.
171. Wieckowska, A; McCullough, AJ; Feldstein, AE. Noninvasive diagnosis and monitoring of nonalcoholic steatohepatitis: present and future. Hepatology, 2007, 46, 582-589.
172. Castera, L; Negre, I; Samii, K; Buffet, C. Pain experienced during percutaneous liver biopsy. Hepatology, 1999, 30, 1529-1530.
173. Grant, A; Neuberger, J. Guidelines on the use of liver biopsy in clinical practice. British Society of Gastroenterology. Gut, 1999, 45 SUPPL 4, IV1-IV11.
174. Gilmore, IT; Burroughs, A; Murray-Lyon, IM; Williams, R; Jenkins, D; Hopkins, A. Indications, methods, and outcomes of percutaneous liver biopsy in England and Wales: an audit by the British Society of Gastroenterology and the Royal College of Physicians of London. Gut, 1995, 36, 437-441.
175. Rantala, AO; Lilja, M; Kauma, H; Savolainen, MJ; Reunanen, A; Kesaniemi, YA. Gamma-glutamyl transpeptidase and the metabolic syndrome. J Intern Med, 2000, 248, 230-238.
176. Marchesini, G; Brizi, M; Bianchi, G; Tomassetti, S; Bugianesi, E; Lenzi, M; McCullough, AJ; Natale, S; Forlani, G; Melchionda, N. Nonalcoholic fatty liver disease: a feature of the metabolic syndrome. Diabetes, 2001, 50, 1844-1850.
177. Sheth, SG; Flamm, SL; Gordon, FD; Chopra, S. AST/ALT ratio predicts cirrhosis in patients with chronic hepatitis C virus infection. Am J Gastroenterol, 1998, 93, 44-48.
178. Brunt, EM; Neuschwander-Tetri, BA; Oliver, D; Wehmeier, KR; Bacon, BR. Nonalcoholic steatohepatitis: histologic features and clinical correlations with 30 blinded biopsy specimens. Hum Pathol, 2004, 35, 1070-1082.
179. Radetti, G; Kleon, W; Stuefer, J; Pittschieler, K. Non-alcoholic fatty liver disease in obese children evaluated by magnetic resonance imaging. Acta Paediatr, 2006, 95, 833-837.
180. Palekar, NA; Naus, R; Larson, SP; Ward, J; Harrison, SA. Clinical model for distinguishing nonalcoholic steatohepatitis from simple steatosis in patients with nonalcoholic fatty liver disease. Liver Int, 2006, 26, 151-156.
181. Zylberberg, H; Rimaniol, AC; Pol, S; Masson, A; De Groote, D; Berthelot, P; Bach, JF; Brechot, C; Zavala, F. Soluble tumor necrosis factor receptors in chronic hepatitis C: a correlation with histological fibrosis and activity. J Hepatol, 1999, 30, 185-191.
182. Sasaki, N; Ueno, T; Morita, Y; Nagata, E; Sata, M. Usefulness of serum hepatic fibrosis markers in the diagnosis of nonalcoholic steatohepatitis (NASH). Hepatogastroenterology, 2006, 53, 678-681.
183. Lydatakis, H; Hager, IP; Kostadelou, E; Mpousmpoulas, S; Pappas, S; Diamantis, I. Non-invasive markers to predict the liver fibrosis in non-alcoholic fatty liver disease. Liver Int, 2006, 26, 864-871.
184. Luo, R; Yang, S; Xie, J; Zhao, Z; He, Y; Yao, J. [Diagnostic value of five serum markers for liver fibrosis]. Zhonghua Gan Zang Bing Za Zhi, 2001, 9, 148-150.
185. Santos, VN; Leite-Mor, MM; Kondo, M; Martins, JR; Nader, H; Lanzoni, VP; Parise, ER. Serum laminin, type IV collagen and hyaluronan as fibrosis markers in non-alcoholic fatty liver disease. Braz J Med Biol Res, 2005, 38, 747-753.
186. Sakugawa, H; Nakayoshi, T; Kobashigawa, K; Yamashiro, T; Maeshiro, T; Miyagi, S; Shiroma, J; Toyama, A; Nakayoshi, T; Kinjo, F; Saito, A. Clinical usefulness of biochemical markers of liver fibrosis in patients with nonalcoholic fatty liver disease. World J Gastroenterol, 2005, 11, 255-259.
187. Miele, L; Forgione, A; Gasbarrini, G; Grieco, A. Noninvasive assessment of fibrosis in non-alcoholic fatty liver disease (NAFLD) and non-alcoholic steatohepatitis (NASH). Transl Res, 2007, 149, 114-125.
188. Rosenberg, WM; Voelker, M; Thiel, R; Becka, M; Burt, A; Schuppan, D; Hubscher, S; Roskams, T; Pinzani, M; Arthur, MJ. Serum markers detect the presence of liver fibrosis: a cohort study. Gastroenterology, 2004, 127, 1704-1713.
189. Guha, IN; Parkes, J; Roderick, P; Chattopadhyay, D; Cross, R; Harris, S; Kaye, P; Burt, AD; Ryder, SD; Aithal, GP; Day, CP; Rosenberg, WM. Noninvasive markers of fibrosis in nonalcoholic fatty liver disease: Validating the European Liver Fibrosis Panel and exploring simple markers. Hepatology, 2008, 47, 455-460.
190. Poynard, T; Ratziu, V; Charlotte, F; Messous, D; Munteanu, M; Imbert-Bismut, F; Massard, J; Bonyhay, L; Tahiri, M; Thabut, D; Cadranel, JF; Le Bail, B; de Ledinghen, V. Diagnostic value of biochemical markers (NashTest) for the prediction of non alcoholo steato hepatitis in patients with non-alcoholic fatty liver disease. BMC Gastroenterol, 2006, 6, 34.
191. Gholam, PM; Flancbaum, L; Machan, JT; Charney, DA; Kotler, DP. Nonalcoholic fatty liver disease in severely obese subjects. Am J Gastroenterol, 2007, 102, 399-408.
192. Ratziu, V; Giral, P; Charlotte, F; Bruckert, E; Thibault, V; Theodorou, I; Khalil, L; Turpin, G; Opolon, P; Poynard, T. Liver fibrosis in overweight patients. Gastroenterology, 2000, 118, 1117-1123.
193. Angulo, P; Hui, JM; Marchesini, G; Bugianesi, E; George, J; Farrell, GC; Enders, F; Saksena, S; Burt, AD; Bida, JP; Lindor, K; Sanderson, SO; Lenzi, M; Adams, LA; Kench, J; Therneau, TM; Day, CP. The NAFLD fibrosis score: a noninvasive system that identifies liver fibrosis in patients with NAFLD. Hepatology, 2007, 45, 846-854.
194. Harrison, SA; Oliver, D; Arnold, HL; Gogia, S; Neuschwander-Tetri, BA. Development and validation of a simple NAFLD clinical scoring system for identifying patients without advanced disease. Gut, 2008, 57, 1441-1447.
195. Schuchmann, S; Weigel, C; Albrecht, L; Kirsch, M; Lemke, A; Lorenz, G; Warzok, R; Hosten, N. Non-invasive quantification of hepatic fat fraction by fast 1.0, 1.5 and 3.0 T MR imaging. Eur J Radiol, 2007, 62, 416-422.
196. Adams, LA; Talwalkar, JA. Diagnostic evaluation of nonalcoholic fatty liver disease. J Clin Gastroenterol, 2006, 40 SUPPL 1, S34-38.
197. Charatcharoenwitthaya, P; Lindor, KD. Role of radiologic modalities in the management of non-alcoholic steatohepatitis. Clin Liver Dis, 2007, 11, 37-54, viii.
198. Nugent, C; Younossi, ZM. Evaluation and management of obesity-related nonalcoholic fatty liver disease. Nat Clin Pract Gastroenterol Hepatol, 2007, 4, 432-441.
199. Mottin, CC; Moretto, M; Padoin, AV; Swarowsky, AM; Toneto, MG; Glock, L; Repetto, G. The role of ultrasound in the diagnosis of hepatic steatosis in morbidly obese patients. Obes Surg, 2004, 14, 635-637.
200. Kawata, R; Sakata, K; Kunieda, T; Saji, S; Doi, H; Nozawa, Y. Quantitative evaluation of fatty liver by computed tomography in rabbits. Am J Roentgenol, 1984, 142, 741-746.
201. Joy, D; Thava, VR; Scott, BB. Diagnosis of fatty liver disease: is biopsy necessary? Eur J Gastroenterol Hepatol, 2003, 15, 539-543.
202. Oliva, MR; Mortele, KJ; Segatto, E; Glickman, JN; Erturk, SM; Ros, PR; Silverman, SG. Computed tomography features of nonalcoholic steatohepatitis with histopathologic correlation. J Comput Assist Tomogr, 2006, 30, 37-43.
203. Saadeh, S; Younossi, ZM; Remer, EM; Gramlich, T; Ong, JP; Hurley, M; Mullen, KD; Cooper, JN; Sheridan, MJ. The utility of radiological imaging in nonalcoholic fatty liver disease. Gastroenterology, 2002, 123, 745-750.
204. Devynck, MA; Simon, A; Pernollet, MG; Chironi, G; Gariepy, J; Rendu, F; Levenson, J. Plasma cGMP and large artery remodeling in asymptomatic men. Hypertension, 2004, 44, 919-923.
205. Rofsky, NM; Weinreb, JC; Ambrosino, MM; Safir, J; Krinsky, G. Comparison between in-phase and opposed-phase T1-weighted breath-hold FLASH sequences for hepatic imaging. J Comput Assist Tomogr, 1996, 20, 230-235.
206. Valls, C; Iannacconne, R; Alba, E; Murakami, T; Hori, M; Passariello, R; Vilgrain, V. Fat in the liver: diagnosis and characterization. Eur Radiol, 2006, 16, 2292-2308.
207. Shimano, H; Horton, JD; Hammer, RE; Shimomura, I; Brown, MS; Goldstein, JL. Overproduction of cholesterol and fatty acids causes massive liver enlargement in transgenic mice expressing truncated SREBP-1a. J Clin Invest, 1996, 98, 1575-1584.
208. Shimomura, I; Hammer, RE; Richardson, JA; Ikemoto, S; Bashmakov, Y; Goldstein, JL; Brown, MS. Insulin resistance and diabetes mellitus in transgenic mice expressing nuclear SREBP-1c in adipose tissue: model for congenital generalized lipodystrophy. Genes Dev, 1998, 12, 3182-3194.
209. Moitra, J; Mason, MM; Olive, M; Krylov, D; Gavrilova, O; Marcus-Samuels, B; Feigenbaum, L; Lee, E; Aoyama, T; Eckhaus, M; Reitman, ML; Vinson, C. Life without white fat: a transgenic mouse. Genes Dev, 1998, 12, 3168-3181.
210. Wang, ND; Finegold, MJ; Bradley, A; Ou, CN; Abdelsayed, SV; Wilde, MD; Taylor, LR; Wilson, DR; Darlington, GJ. Impaired energy homeostasis in C/EBP alpha knockout mice. Science, 1995, 269, 1108-1112.
211. Darlington, GJ; Wang, N; Hanson, RW. C/EBP alpha: a critical regulator of genes governing integrative metabolic processes. Curr Opin Genet Dev, 1995, 5, 565-570.
212. Akira, S. Functional roles of STAT family proteins: lessons from knockout mice. Stem Cells, 1999, 17, 138-146.
213. Udy, GB; Towers, RP; Snell, RG; Wilkins, RJ; Park, SH; Ram, PA; Waxman, DJ; Davey, HW. Requirement of STAT5b for sexual dimorphism of body growth rates and liver gene expression. Proc Natl Acad Sci, U S A, 1997, 94, 7239-7244.
214. Campfield, LA; Smith, FJ; Burn, P. The OB protein (leptin) pathway--a link between adipose tissue mass and central neural networks. Horm Metab Res, 1996, 28, 619-632.
215. Pelleymounter, MA; Cullen, MJ; Baker, MB; Hecht, R; Winters, D; Boone, T; Collins, F. Effects of the obese gene product on body weight regulation in ob/ob mice. Science, 1995, 269, 540-543.
216. Chen, H; Charlat, O; Tartaglia, LA; Woolf, EA; Weng, X; Ellis, SJ; Lakey, ND; Culpepper, J; Moore, KJ; Breitbart, RE; Duyk, GM; Tepper, RI; Morgenstern, JP. Evidence that the diabetes gene encodes the leptin receptor: identification of a mutation in the leptin receptor gene in db/db mice. Cell, 1996, 84, 491-495.
217. Ghilardi, N; Ziegler, S; Wiestner, A; Stoffel, R; Heim, MH; Skoda, RC. Defective STAT signaling by the leptin receptor in diabetic mice. Proc Natl Acad Sci, U S A, 1996, 93, 6231-6235.
218. Lee, GH; Proenca, R; Montez, JM; Carroll, KM; Darvishzadeh, JG; Lee, JI; Friedman, JM. Abnormal splicing of the leptin receptor in diabetic mice. Nature, 1996, 379, 632-635.
219. Phillips, MS; Liu, Q; Hammond, HA; Dugan, V; Hey, PJ; Caskey, CJ; Hess, JF. Leptin receptor missense mutation in the fatty Zucker rat. Nat Genet, 1996, 13, 18-19.
220. Kersten, S; Seydoux, J; Peters, JM; Gonzalez, FJ; Desvergne, B; Wahli, W. Peroxisome proliferator-activated receptor alpha mediates the adaptive response to fasting. J Clin Invest, 1999, 103, 1489-1498.
221. Koizumi, T; Nikaido, H; Hayakawa, J; Nonomura, A; Yoneda, T. Infantile disease with microvesicular fatty infiltration of viscera spontaneously occurring in the C3H-H-2(0) strain of mouse with similarities to Reye's syndrome. Lab Anim, 1988, 22, 83-87.
222. Kuwajima, M; Kono, N; Horiuchi, M; Imamura, Y; Ono, A; Inui, Y; Kawata, S; Koizumi, T; Hayakawa, J; Saheki, T; et al. Animal model of systemic carnitine deficiency: analysis in C3H-H-2 degrees strain of mouse associated with juvenile visceral steatosis. Biochem Biophys Res Commun, 1991, 174, 1090-1094.
223. Collins, S; Martin, TL; Surwit, RS; Robidoux, J. Genetic vulnerability to diet-induced obesity in the C57BL/6J mouse: physiological and molecular characteristics. Physiol Behav, 2004, 81, 243-248.
224. Winzell, MS; Ahren, B. The high-fat diet-fed mouse: a model for studying mechanisms and treatment of impaired glucose tolerance and type 2 diabetes. Diabetes, 2004, 53 SUPPL 3, S215-219.
225. Feldstein, AE; Canbay, A; Guicciardi, ME; Higuchi, H; Bronk, SF; Gores, GJ. Diet associated hepatic steatosis sensitizes to Fas mediated liver injury in mice. J Hepatol, 2003, 39, 978-983.
226. Li, Z; Soloski, MJ; Diehl, AM. Dietary factors alter hepatic innate immune system in mice with nonalcoholic fatty liver disease. Hepatology, 2005, 42, 880-885.
227. Slott, PA; Liu, MH; Tavoloni, N. Origin, pattern, and mechanism of bile duct proliferation following biliary obstruction in the rat. Gastroenterology, 1990, 99, 466-477.
228. Kinnman, N; Francoz, C; Barbu, V; Wendum, D; Rey, C; Hultcrantz, R; Poupon, R; Housset, C. The myofibroblastic conversion of peribiliary fibrogenic cells distinct from hepatic stellate cells is stimulated by platelet-derived growth factor during liver fibrogenesis. Lab Invest, 2003, 83, 163-173.
229. Sedlaczek, N; Jia, JD; Bauer, M; Herbst, H; Ruehl, M; Hahn, EG; Schuppan, D. Proliferating bile duct epithelial cells are a major source of connective tissue growth factor in rat biliary fibrosis. The American journal of pathology, 2001, 158, 1239-1244.
230. Desmouliere, A; Darby, I; Costa, AM; Raccurt, M; Tuchweber, B; Sommer, P; Gabbiani, G. Extracellular matrix deposition, lysyl oxidase expression, and myofibroblastic differentiation during the initial stages of cholestatic fibrosis in the rat. Lab Invest, 1997, 76, 765-778.
231. Ito, M; Suzuki, J; Tsujioka, S; Sasaki, M; Gomori, A; Shirakura, T; Hirose, H; Ito, M; Ishihara, A; Iwaasa, H; Kanatani, A. Longitudinal analysis of murine steatohepatitis model induced by chronic exposure to high-fat diet. Hepatol Res, 2007, 37, 50-57.
232. Ip, E; Farrell, G; Hall, P; Robertson, G; Leclercq, I. Administration of the potent PPARalpha agonist, Wy-14,643, reverses nutritional fibrosis and steatohepatitis in mice. Hepatology, 2004, 39, 1286-1296.
233. Larter, CZ; Yeh, MM; Williams, J; Bell-Anderson, KS; Farrell, GC. MCD-induced steatohepatitis is associated with hepatic adiponectin resistance and adipogenic transformation of hepatocytes. J Hepatol, 2008, 49, 407-416.
234. Kudo, H; Yata, Y; Takahara, T; Kawai, K; Nakayama, Y; Kanayama, M; Oya, T; Morita, S; Sasahara, M; Mann, DA; Sugiyama, T. Telmisartan attenuates progression of steatohepatitis in mice: role of hepatic macrophage infiltration and effects on adipose tissue. Liver Int, 2009.
235. Cong, WN; Tao, RY; Tian, JY; Liu, GT; Ye, F. The establishment of a novel non-alcoholic steatohepatitis model accompanied with obesity and insulin resistance in mice. Life Sci, 2008, 82, 983-990.
236. Svegliati-Baroni, G; Candelaresi, C; Saccomanno, S; Ferretti, G; Bachetti, T; Marzioni, M; De Minicis, S; Nobili, L; Salzano, R; Omenetti, A; Pacetti, D; Sigmund, S; Benedetti, A; Casini, A. A model of insulin resistance and nonalcoholic steatohepatitis in rats: role of peroxisome proliferator-activated receptor-alpha and n-3 polyunsaturated fatty acid treatment on liver injury. Am J Pathol, 2006, 169, 846-860.
237. George, J; Pera, N; Phung, N; Leclercq, I; Yun Hou, J; Farrell, G. Lipid peroxidation, stellate cell activation and hepatic fibrogenesis in a rat model of chronic steatohepatitis. J Hepatol, 2003, 39, 756-764.